LIL-HM14D-100μg / 询价
LIL-HM14D-500μg / 询价
LIL-HM14D-500μgx2 / 询价
Human LILRB4/CD85k/ILT3 Domain1&2 Protein
Recombinant Human LILRB4/CD85k/ILT3 Domain1&2 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Pro27-Ser218.[Accession | AAH26309]
The protein has a predicted MW of 22.9 kDa. Due to glycosylation, the protein migrates to 23-25 kDa based on Tris-Bis PAGE result.
Less than 1EU per μg by the LAL method.
> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC
Supplied as 0.22μm filtered solution in 20mM Tris, 150mM NaCl (pH 8.2).
Valid for 12 months from date of receipt when stored at -80°C.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human LILRB4 Domain1&2 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
The purity of Human LILRB4 Domain1&2 is greater than 95% as determined by SEC-HPLC.
Immobilized Human LILRB4 Domain 1&2, His Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Anti-LILRB4 Antibody, hFc Tag with the EC50 of 18.2ng/ml determined by ELISA.
LILRB4,also known as CD85k and LIR-5, ILT3, is an approximately 60 kDa transmembrane glycoprotein that negatively regulates immune cell activation. Mature human ILT3 consists of a 238 amino acid (aa) extracellular domain with two Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM).LILRB4 is receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles.
HM18; ILT3; ILT-3; LILRB4; LIR5; CD85K
(1)Samuel J , Heyu C , Mi D , et al. A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML[J]. Molecular Therapy, 2018:S1525001618303721-.
